KR101357204B1 - 바리셀라 조스터 바이러스 백신 - Google Patents

바리셀라 조스터 바이러스 백신 Download PDF

Info

Publication number
KR101357204B1
KR101357204B1 KR1020077022672A KR20077022672A KR101357204B1 KR 101357204 B1 KR101357204 B1 KR 101357204B1 KR 1020077022672 A KR1020077022672 A KR 1020077022672A KR 20077022672 A KR20077022672 A KR 20077022672A KR 101357204 B1 KR101357204 B1 KR 101357204B1
Authority
KR
South Korea
Prior art keywords
vzv
antigen
vaccine
years old
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020077022672A
Other languages
English (en)
Korean (ko)
Other versions
KR20070110413A (ko
Inventor
엠마뉴엘 줄레스 하논
진 스테펜
Original Assignee
글락소스미스클라인 바이오로지칼즈 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34430592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101357204(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 글락소스미스클라인 바이오로지칼즈 에스.에이. filed Critical 글락소스미스클라인 바이오로지칼즈 에스.에이.
Publication of KR20070110413A publication Critical patent/KR20070110413A/ko
Application granted granted Critical
Publication of KR101357204B1 publication Critical patent/KR101357204B1/ko
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020077022672A 2005-03-03 2006-03-01 바리셀라 조스터 바이러스 백신 Active KR101357204B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0504436.7A GB0504436D0 (en) 2005-03-03 2005-03-03 Vaccine
GB0504436.7 2005-03-03
PCT/EP2006/002070 WO2006094756A2 (en) 2005-03-03 2006-03-01 Varicella zoster virus vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020137034242A Division KR20140006115A (ko) 2005-03-03 2006-03-01 바리셀라 조스터 바이러스 백신

Publications (2)

Publication Number Publication Date
KR20070110413A KR20070110413A (ko) 2007-11-16
KR101357204B1 true KR101357204B1 (ko) 2014-02-06

Family

ID=34430592

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020077022672A Active KR101357204B1 (ko) 2005-03-03 2006-03-01 바리셀라 조스터 바이러스 백신
KR1020137034242A Withdrawn KR20140006115A (ko) 2005-03-03 2006-03-01 바리셀라 조스터 바이러스 백신

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020137034242A Withdrawn KR20140006115A (ko) 2005-03-03 2006-03-01 바리셀라 조스터 바이러스 백신

Country Status (35)

Country Link
US (3) US20080171079A1 (enExample)
EP (4) EP1858917B8 (enExample)
JP (2) JP5420842B2 (enExample)
KR (2) KR101357204B1 (enExample)
CN (2) CN101189254B (enExample)
AR (2) AR052498A1 (enExample)
AU (1) AU2006222225B2 (enExample)
BE (1) BE2018C035I2 (enExample)
BR (1) BRPI0607840B1 (enExample)
CA (2) CA2882255C (enExample)
CY (5) CY1116108T1 (enExample)
DK (4) DK1858917T3 (enExample)
EA (1) EA011884B1 (enExample)
ES (4) ES2618037T3 (enExample)
GB (1) GB0504436D0 (enExample)
HR (4) HRP20150142T1 (enExample)
HU (4) HUE038468T2 (enExample)
IL (1) IL185442A (enExample)
LT (4) LT2281831T (enExample)
LU (1) LUC00087I2 (enExample)
MA (1) MA29714B1 (enExample)
MX (2) MX2007010626A (enExample)
MY (1) MY148464A (enExample)
NL (1) NL300951I2 (enExample)
NO (2) NO341841B1 (enExample)
NZ (1) NZ561075A (enExample)
PE (2) PE20100658A1 (enExample)
PL (4) PL1858917T3 (enExample)
PT (4) PT2301955T (enExample)
SI (4) SI2301955T1 (enExample)
TR (2) TR201809397T4 (enExample)
TW (1) TWI403517B (enExample)
UA (1) UA94900C2 (enExample)
WO (1) WO2006094756A2 (enExample)
ZA (1) ZA200707144B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190121956A (ko) 2018-04-19 2019-10-29 가천대학교 산학협력단 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물
KR20210046634A (ko) 2018-04-19 2021-04-28 가천대학교 산학협력단 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물
WO2021172971A1 (ko) * 2020-02-28 2021-09-02 (주)셀트리온 수두 대상포진 바이러스 융합 단백질 및 이를 포함하는 면역원성 조성물
WO2022010213A1 (ko) 2020-07-10 2022-01-13 주식회사 녹십자 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법
US12527859B2 (en) 2020-09-11 2026-01-20 Eubiologics Co., Ltd. Vaccine composition for chickenpox or Varicella Zoster and method of using same

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
AU2008275895A1 (en) * 2007-07-19 2009-01-22 Novavax, Inc. Varicella Zoster Virus-virus like particles (VLPS) and antigens
FR2952825B1 (fr) 2009-11-24 2012-05-25 Goaster Jacqueline Le Utilisation d'un vaccin contre le virus vzv/hsv3 pour traiter les infections herpetiques par le virus hsv1 et/ou le virus hsv2
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
US10487332B2 (en) 2010-07-06 2019-11-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
DK2590626T3 (en) 2010-07-06 2016-01-25 Glaxosmithkline Biolog Sa Liposomes with lipids having a favorable pKa of RNA for bringing
UA112970C2 (uk) * 2010-08-05 2016-11-25 Мерк Шарп Енд Доме Корп. Інактивований вірус вітряної віспи, спосіб його одержання і застосування
LT3981427T (lt) 2010-08-31 2022-08-10 Glaxosmithkline Biologicals S.A. Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
TR201903651T4 (tr) 2010-10-11 2019-04-22 Glaxosmithkline Biologicals Sa Antijen uygulama platformları.
JP2014522842A (ja) 2011-07-06 2014-09-08 ノバルティス アーゲー 免疫原性組み合わせ組成物およびその使用
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN105530953A (zh) * 2013-10-03 2016-04-27 日东电工株式会社 注射疫苗组合物
JP6499420B2 (ja) * 2014-11-13 2019-04-10 公益財団法人ヒューマンサイエンス振興財団 ワクチン及び感染防御キット
MX2017008055A (es) * 2014-12-18 2017-09-28 Glaxosmithkline Biologicals Sa Vacunacion.
BE1022523B1 (fr) * 2014-12-18 2016-05-20 Glaxosmithkline Biologicals Sa Vaccination
CN117731769A (zh) * 2015-10-22 2024-03-22 摩登纳特斯有限公司 用于水痘带状疱疹病毒(vzv)的核酸疫苗
RS63381B1 (sr) 2015-10-22 2022-08-31 Modernatx Inc Vakcine protiv respiratornih virusa
WO2017079582A1 (en) 2015-11-06 2017-05-11 Adjuvance Technologies, Inc. Triterpene saponin analogues
US10925958B2 (en) 2016-11-11 2021-02-23 Modernatx, Inc. Influenza vaccine
CN110035772B (zh) * 2016-11-25 2023-07-18 财团法人牧岩生命科学研究所 水痘带状疱疹病毒疫苗
WO2018097642A1 (ko) * 2016-11-25 2018-05-31 재단법인 목암생명과학연구소 바리셀라 조스터 바이러스 백신
CN107022559A (zh) * 2016-12-08 2017-08-08 长春祈健生物制品有限公司 一种水痘‑带状疱疹病毒糖蛋白e胞外区蛋白的制备方法
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
CA3048608C (en) 2016-12-26 2021-11-23 Mogam Institute For Biomedical Research Herpes zoster vaccine composition
CN108727503A (zh) * 2017-04-18 2018-11-02 武汉博沃生物科技有限公司 VZV重组gE-鞭毛素融合蛋白及其制备方法和应用
CN110582282A (zh) * 2017-04-25 2019-12-17 佐剂技术公司 三萜皂苷类似物
JP7177082B2 (ja) * 2017-04-25 2022-11-22 アジュバンス・テクノロジーズ・インコーポレーテッド トリテルペンサポニン類似物
US20210187098A1 (en) * 2017-04-28 2021-06-24 Glaxosmithkline Biologicals Sa Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
IE87414B1 (en) 2017-05-30 2023-07-19 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
AU2018350887A1 (en) 2017-10-16 2020-03-05 Adjuvance Technologies, Inc. Triterpene saponin analogues
WO2019106192A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
CN108315344A (zh) * 2018-02-14 2018-07-24 武汉博沃生物科技有限公司 Vzv糖蛋白e基因表达载体及其重组酵母菌株与应用
WO2019225962A1 (ko) * 2018-05-23 2019-11-28 재단법인 목암생명과학연구소 바리셀라 조스터 바이러스의 항원 변이체 및 이의 용도
EP3833382A1 (en) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processes and vaccines
CN108992667A (zh) * 2018-08-09 2018-12-14 安徽智飞龙科马生物制药有限公司 一种带状疱疹疫苗及其制备方法、应用
EP3868399A4 (en) * 2018-09-27 2022-07-20 Bravovax Co., Ltd. IMMUNE COMPOSITION, METHOD FOR PREPARATION AND ASSOCIATED APPLICATION
US12551553B2 (en) 2018-11-29 2026-02-17 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
CN109602901B (zh) * 2019-01-08 2022-05-27 成都迈科康生物科技有限公司 一种带状疱疹病毒疫苗及其制备方法和应用
EP3938379A4 (en) 2019-03-15 2023-02-22 ModernaTX, Inc. Hiv rna vaccines
BR112021024363A2 (pt) 2019-06-05 2022-03-22 Glaxosmithkline Biologicals Sa Purificação de saponina
CN112142828B (zh) * 2019-06-28 2022-02-01 怡道生物科技(苏州)有限公司 一种gE基因及表达该基因的载体
CN112138153B (zh) * 2019-06-28 2022-08-23 怡道生物科技(苏州)有限公司 一种重组带状疱疹疫苗组合物及其用途
EP4074334A4 (en) * 2019-12-13 2024-09-04 Grand Theravac Life Science (Nanjing) Co., Ltd. PHARMACEUTICAL COMPOSITION AND ITS USE
WO2022031359A1 (en) 2020-08-07 2022-02-10 Infectious Disease Research Institute Purified saponins and chromatographic process for purification of same
RU2750818C1 (ru) * 2020-11-19 2021-07-05 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова Вирусный штамм для получения аттенуированной живой культуральной вакцины для профилактики и лечения опоясывающего герпеса для взрослого населения
WO2023056912A1 (en) * 2021-10-08 2023-04-13 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for vzv
WO2023064612A2 (en) 2021-10-15 2023-04-20 BioNTech SE Pharmaceutical compositions for delivery of viral antigens and related methods
WO2023096963A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Varicella-zoster virus immunogen compositions and their uses
CN116327912A (zh) * 2021-12-23 2023-06-27 上海泽润生物科技有限公司 带状疱疹疫苗组合物
CN116350770B (zh) * 2021-12-28 2024-07-12 成都迈科康生物科技有限公司 一种带状疱疹疫苗制剂及其制备方法
EP4558170A1 (en) 2022-07-19 2025-05-28 GlaxoSmithKline Biologicals S.A. Continuous process for vaccine production
CN116655748B (zh) * 2023-02-28 2024-07-26 易慧生物技术(上海)有限公司 一种截短型水痘-带状疱疹病毒gE蛋白及其应用
CN118240844B (zh) * 2024-05-27 2024-12-13 北京悦康科创医药科技股份有限公司 带状疱疹mRNA疫苗及其制备方法和应用
WO2026006687A1 (en) * 2024-06-28 2026-01-02 Orbital Therapeutics, Inc. Circular rna compositions and uses thereof for diseases caused by varicella-zoster virus
CN120081913B (zh) * 2025-05-08 2025-08-12 江苏华诺泰生物医药科技有限公司 一种重组带状疱疹病毒原液的纯化方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043527A1 (en) 1999-01-20 2000-07-27 Smithkline Beecham Biologicals S.A. Varicella-zoster virus vaccines
WO2002032450A2 (en) 2000-10-18 2002-04-25 Glaxosmithkline Biologicals S.A. Vaccines

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5341202B2 (enExample) 1974-03-12 1978-11-01
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4769239A (en) 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0405867B1 (en) 1989-06-27 1995-03-15 SMITHKLINE BEECHAM BIOLOGICALS s.a. Novel compounds
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
CA2085827C (en) 1991-12-23 2003-10-14 Lucas A. T. Hilgers Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
CZ282235B6 (cs) * 1992-06-25 1997-06-11 Smithkline Beecham Biologicals (S.A.) Očkovací prostředek, jeho použití k výrobě vakcíny, způsob léčby patogenních infekcí tímto prostředkem a způsob jeho výroby
ATE210722T1 (de) 1992-07-17 2001-12-15 Merck & Co Inc Methode zur verhinderung von zoster und linderung der mit varicellea verbundenen postherpetischen neuralgie
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
US5976552A (en) * 1995-04-28 1999-11-02 Protein Sciences Corporation Virus vaccines
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
EP0817847B2 (en) * 1995-03-23 2009-09-09 Immunex Corporation Il-17 receptor
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
KR0177323B1 (ko) * 1996-02-16 1999-04-01 성재갑 바이러스 백신 생산에 유용한 사람 이배체 폐세포 및 이를 이용한 수두 백신의 제조방법
KR100603884B1 (ko) 1997-04-01 2006-07-24 코리사 코퍼레이션 모노포스포릴 지질 ａ의 수성 면역적 아쥬반트 조성물
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
DE69815692T2 (de) 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. Öl in wasser emulsionen mit saponinen
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043527A1 (en) 1999-01-20 2000-07-27 Smithkline Beecham Biologicals S.A. Varicella-zoster virus vaccines
WO2002032450A2 (en) 2000-10-18 2002-04-25 Glaxosmithkline Biologicals S.A. Vaccines

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190121956A (ko) 2018-04-19 2019-10-29 가천대학교 산학협력단 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물
KR20210046634A (ko) 2018-04-19 2021-04-28 가천대학교 산학협력단 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물
WO2021172971A1 (ko) * 2020-02-28 2021-09-02 (주)셀트리온 수두 대상포진 바이러스 융합 단백질 및 이를 포함하는 면역원성 조성물
WO2022010213A1 (ko) 2020-07-10 2022-01-13 주식회사 녹십자 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법
US12527859B2 (en) 2020-09-11 2026-01-20 Eubiologics Co., Ltd. Vaccine composition for chickenpox or Varicella Zoster and method of using same

Also Published As

Publication number Publication date
DK2281831T3 (en) 2018-06-14
KR20070110413A (ko) 2007-11-16
NO2018033I1 (no) 2018-09-20
TR201809397T4 (tr) 2018-07-23
UA94900C2 (uk) 2011-06-25
EP1858917A2 (en) 2007-11-28
HUE038468T2 (hu) 2018-10-29
PE20061287A1 (es) 2006-12-07
PE20100658A1 (es) 2010-10-23
EP2301955A2 (en) 2011-03-30
EA200701632A1 (ru) 2008-02-28
PL2281831T3 (pl) 2018-08-31
WO2006094756A2 (en) 2006-09-14
BRPI0607840A2 (pt) 2009-06-13
US20080171079A1 (en) 2008-07-17
ZA200707144B (en) 2009-11-25
CA2882255C (en) 2018-03-27
PL2301955T3 (pl) 2018-08-31
CN103028113A (zh) 2013-04-10
US7939084B1 (en) 2011-05-10
BE2018C035I2 (enExample) 2025-09-05
CN103028113B (zh) 2015-05-20
US20110104260A1 (en) 2011-05-05
CY1118629T1 (el) 2017-07-12
LTPA2018012I1 (lt) 2018-11-12
TR201809393T4 (tr) 2018-07-23
AU2006222225B2 (en) 2012-08-16
LTC2281831I2 (lt) 2020-08-25
HRP20180989T1 (hr) 2018-08-10
SI1858917T1 (sl) 2015-03-31
AR107285A2 (es) 2018-04-18
LT2281830T (lt) 2017-02-10
EP1858917B1 (en) 2014-12-24
HRP20170081T1 (hr) 2017-03-24
MA29714B1 (fr) 2008-09-01
HRP20180988T1 (hr) 2018-08-10
JP2013144710A (ja) 2013-07-25
ES2675055T3 (es) 2018-07-06
ES2618037T3 (es) 2017-06-20
JP2008531637A (ja) 2008-08-14
EP2281831B1 (en) 2018-04-18
GB0504436D0 (en) 2005-04-06
CY1116108T1 (el) 2017-02-08
ES2532803T3 (es) 2015-03-31
MX346865B (es) 2017-04-04
NO341841B1 (no) 2018-02-05
EP2281831A2 (en) 2011-02-09
NO20074392L (no) 2007-11-27
SI2281831T1 (en) 2018-07-31
EP2281830A2 (en) 2011-02-09
MY148464A (en) 2013-04-30
AR052498A1 (es) 2007-03-21
CY2018025I2 (el) 2018-12-12
SI2281830T1 (sl) 2017-03-31
PL2281830T3 (pl) 2017-06-30
PL1858917T3 (pl) 2015-05-29
PT1858917E (pt) 2015-02-24
DK1858917T3 (da) 2015-02-02
DK2281830T3 (en) 2017-03-20
EP2301955B1 (en) 2018-04-18
EP1858917B8 (en) 2015-05-06
US20110045059A1 (en) 2011-02-24
NL300951I2 (nl) 2020-08-31
TWI403517B (zh) 2013-08-01
IL185442A0 (en) 2008-01-06
KR20140006115A (ko) 2014-01-15
JP5840167B2 (ja) 2016-01-06
CA2600905C (en) 2015-05-05
MX2007010626A (es) 2007-10-16
CA2600905A1 (en) 2006-09-14
NL300951I1 (nl) 2018-09-26
SI2301955T1 (en) 2018-07-31
CN101189254B (zh) 2013-05-22
LT2281831T (lt) 2018-07-10
JP5420842B2 (ja) 2014-02-19
LUC00087I2 (enExample) 2018-11-26
ES2675054T3 (es) 2018-07-06
CY2018025I1 (el) 2018-12-12
IL185442A (en) 2013-07-31
CA2882255A1 (en) 2006-09-14
PT2281830T (pt) 2017-02-24
BRPI0607840B1 (pt) 2021-06-29
PT2301955T (pt) 2018-06-18
PT2281831T (pt) 2018-06-15
LT2301955T (lt) 2018-07-10
EP2281830A3 (en) 2012-01-25
DK2301955T3 (en) 2018-06-14
HK1111427A1 (en) 2008-08-08
EP2301955A3 (en) 2011-11-16
EP2281830B1 (en) 2016-12-21
CY1120347T1 (el) 2018-12-12
HUS1800038I1 (hu) 2018-10-29
HRP20150142T1 (hr) 2015-05-22
EA011884B1 (ru) 2009-06-30
TW200643028A (en) 2006-12-16
AU2006222225A1 (en) 2006-09-14
EP2281831A3 (en) 2011-11-16
HUE038467T2 (hu) 2018-10-29
CY1121211T1 (el) 2020-05-29
HUE032544T2 (en) 2017-10-30
CN101189254A (zh) 2008-05-28
WO2006094756A3 (en) 2007-02-15
NZ561075A (en) 2009-06-26

Similar Documents

Publication Publication Date Title
KR101357204B1 (ko) 바리셀라 조스터 바이러스 백신
AU2012213948B2 (en) Vaccine
HK1111427B (en) Varicella zoster virus vaccine
HK1147272A (en) Varicella zoster virus vaccine
HK1147273A (en) Varicella zoster virus vaccine
HK1156325A (en) Varicella zoster virus vaccine

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20161229

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20171228

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20181227

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

S17-X000 Non-exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S17-lic-X000

A101 Application to extend term of patent right by permit
PA0101 Application to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G18-tex-PA0101

Protection beyond ip right term event data comment text: Claim Total Quantity : 12, Claim Number : 1 3, 5 7 9 14, Period Limitation Text : 1826, Comment Text : 296

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PE0702 Decision to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G20-tex-PE0702

Protection beyond ip right term event data comment text: Claim Total Quantity : 12, Claim Number : 1 3, 5 7 9 14, Period Limitation Text : 1826, Comment Text : 296

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 13

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 13